Literature DB >> 10197215

Systemic activity of inhaled and swallowed beclomethasone dipropionate and the effect of different inhaler devices.

C Trescoli1, M J Ward.   

Abstract

Inhaled glucocorticoids such as beclomethasone dipropionate, which are used in the treatment of asthma, may be associated with systemic adverse effects. To determine whether any systemic absorption following the inhalation of beclomethasone was a result of drug being absorbed from the lung (inhaled fraction) or the gastrointestinal tract (swallowed fraction), we studied normal subjects after the inhalation or swallowing of 2 mg beclomethasone dipropionate. Systemic activity was assessed using early morning cortisol suppression. Both inhaled and swallowed fractions produced significant systemic activity, the degree of which depended on the inhaler device used. Systemic activity was greater using a dry powder inhaler (52%) than using a metered dose inhaler with a large volume spacer (28%). These findings suggest that to limit potential adverse effects from high-dose beclomethasone dipropionate it is better to use a metered dose aerosol with large volume spacer than a dry powder.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 10197215      PMCID: PMC2431615          DOI: 10.1136/pgmj.74.877.675

Source DB:  PubMed          Journal:  Postgrad Med J        ISSN: 0032-5473            Impact factor:   2.401


  9 in total

1.  Morning serum cortisol concentrations after 2 mg inhaled beclomethasone dipropionate in normal subjects: effect of a 750 ml spacing device.

Authors:  M Farrer; A J Francis; S J Pearce
Journal:  Thorax       Date:  1990-10       Impact factor: 9.139

2.  Hypertrophic pulmonary osteoarthropathy in a patient with pulmonary alveolar microlithiasis.

Authors:  S Emri; L Cöplü; Z T Selçuk; A A Sahin; Y I Baris
Journal:  Thorax       Date:  1991-02       Impact factor: 9.139

3.  Beclomethasone inhalation decreases serum osteocalcin concentrations.

Authors:  E M Pouw; M F Prummel; H Oosting; C M Roos; E Endert
Journal:  BMJ       Date:  1991-03-16

Review 4.  New perspectives on inhaled drug delivery and systemic bioactivity.

Authors:  B J Lipworth
Journal:  Thorax       Date:  1995-02       Impact factor: 9.139

5.  Pharmacokinetics and metabolism of budesonide, a selective glucocorticoid.

Authors:  A Ryrfeldt; P Andersson; S Edsbäcker; M Tönnesson; D Davies; R Pauwels
Journal:  Eur J Respir Dis Suppl       Date:  1982

6.  Lung deposition patterns of directly labelled salbutamol in normal subjects and in patients with reversible airflow obstruction.

Authors:  R Melchor; M F Biddiscombe; V H Mak; M D Short; S G Spiro
Journal:  Thorax       Date:  1993-05       Impact factor: 9.139

7.  Effect of a volumatic spacer and mouth rinsing on systemic absorption of inhaled corticosteroids from a metered dose inhaler and dry powder inhaler.

Authors:  O Selroos; M Halme
Journal:  Thorax       Date:  1991-12       Impact factor: 9.139

8.  The human pharmacology of fluticasone propionate.

Authors:  S M Harding
Journal:  Respir Med       Date:  1990-11       Impact factor: 3.415

9.  Steroid-induced fractures and bone loss in patients with asthma.

Authors:  A D Adinoff; J R Hollister
Journal:  N Engl J Med       Date:  1983-08-04       Impact factor: 91.245

  9 in total
  1 in total

1.  Risk of adverse gastrointestinal events from inhaled corticosteroids.

Authors:  Richard A Hansen; Wanzhu Tu; Jane Wang; Roberta Ambuehl; Clement J McDonald; Michael D Murray
Journal:  Pharmacotherapy       Date:  2008-11       Impact factor: 4.705

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.